首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Diffuse intrinsic pontine gliomas: Diagnostic approach and treatment strategies
【24h】

Diffuse intrinsic pontine gliomas: Diagnostic approach and treatment strategies

机译:弥漫性内在猪胶石:诊断方法和治疗策略

获取原文
获取原文并翻译 | 示例
       

摘要

Diffuse intrinsic pontine gliomas (DIPG) are high grade gliomas of the brainstem with fatal outcomes. Radiation is known to be partially effective to control the immediate flare but relapse is frequent. There has been ongoing research to study the role of molecular subgroups and identification of specific targets but this is not possible with histopathological diagnosis alone. The authors objective is to highlight the need for and discuss ongoing molecular research. There is an inherent need for the availability of tumor tissue to be able to conduct research studies. The authors advocate the use of neuronavigation assisted stereotactic technique for tumor biopsy. The technique is feasible with a predefined surgical trajectory. After obtaining tissue diagnosis further work can be performed to isolate and identify histone protein genetic mutations and methylation changes responsible for DIPG molecular subgrouping. Moreover, convection enhanced delivery of therapeutic agents is being developed for better instillation of future drug agents. Despite identification of genetic/epigenetic mutations, growth factors, receptors, and tissue biomarkers, the oncogenesis of DIPG remains elusive. The authors effort to provide a comprehensive review on DIPG to better understand the disease, need for tissue diagnosis, described surgical technique, and need for pre-clinical and clinical future research is novel. (C) 2019 Elsevier Ltd. All rights reserved.
机译:弥漫性内在猪胶质瘤(DIPG)是脑干的高级胶质瘤,具有致命的结果。已知辐射是部分有效地控制立即光晕,但复发频繁。已经持续研究了研究分子亚组的作用和鉴定特定靶标,但单独的组织病理学诊断是不可能的。作者目的是突出需要并讨论正在进行的分子研究。肿瘤组织的可用性是能够进行研究研究的固有的需求。作者倡导使用神经道vigiggation辅助立体定向技术进行肿瘤活组织检查。该技术可行,具有预定义的手术轨迹。在获得组织诊断后,可以进行进一步的作用以分离和鉴定负责DIPG分子亚组的组蛋白蛋白遗传突变和甲基化变化。此外,正在开发对治疗剂的转向增强的递送,以便更好地滴注未来的药物。尽管鉴定遗传/表观遗传突变,生长因子,受体和组织生物标志物,但DIPG的肿瘤发生仍然难以捉摸。作者努力为DIPG提供全面的审查,以更好地了解疾病,需要组织诊断,描述手术技术,并需要进行临床前和临床未来的研究是新颖的。 (c)2019年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号